-
-
-
-
-
-
-
Esperion to be Acquired by ARCHIMED
-
-
-
-
-
-
-
Esperion presents stroke reduction data for NEXLETOL at cardiology conference
-
-
-
-
-
-
-
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
-
-
-
-
-
-
-
Esperion Therapeutics (ESPR) Appoints Craig Thompson to its Board
-
-
-
-
-
-
-
Esperion Appoints Benjamin O. Looker as General Counsel
-
-
-
-
-
-
-
Esperion Therapeutics (ESPR) and Oberland Capital Announce $200 Million Funding Agreement
-
1,157,750 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

